tetano
Editor, Senior Moderator
Mult Scler Relat Disord
. 2020 Jun 26;44:102341.
doi: 10.1016/j.msard.2020.102341. Online ahead of print.
Negative SARS-CoV-2 Antibody Testing Following COVID-19 Infection in Two MS Patients Treated With Ocrelizumab
Jeanine Rempe Thornton[SUP] 1 [/SUP], Asaff Harel[SUP] 2 [/SUP]
Affiliations
Abstract
Background: It is unknown whether MS disease modifying therapies impact ability to mount an antibody response to SARS-CoV-2.
Methods: Case series and literature review. We report a series of two MS patients who developed COVID-19 while on Ocrelizumab therapy and subsequently exhibited negative SARS-CoV-2 serology.
Results: A 42-year-old man and 39-year-old woman with MS developed COVID-19 while on Ocrelizumab therapy. Neither patient required hospitalization. The man exhibited negative serology at 7- and 9-weeks post-infection. The woman exhibited negative serology at 6- and 12-weeks post-infection.
Conclusions: Large studies are essential to determine whether certain DMTs may blunt SARS-CoV-2 antibody production.
Keywords: Antibodies; COVID-19; Coronavirus; Multiple sclerosis; Ocrelizumab.
. 2020 Jun 26;44:102341.
doi: 10.1016/j.msard.2020.102341. Online ahead of print.
Negative SARS-CoV-2 Antibody Testing Following COVID-19 Infection in Two MS Patients Treated With Ocrelizumab
Jeanine Rempe Thornton[SUP] 1 [/SUP], Asaff Harel[SUP] 2 [/SUP]
Affiliations
- PMID: 32622338
- DOI: 10.1016/j.msard.2020.102341
Abstract
Background: It is unknown whether MS disease modifying therapies impact ability to mount an antibody response to SARS-CoV-2.
Methods: Case series and literature review. We report a series of two MS patients who developed COVID-19 while on Ocrelizumab therapy and subsequently exhibited negative SARS-CoV-2 serology.
Results: A 42-year-old man and 39-year-old woman with MS developed COVID-19 while on Ocrelizumab therapy. Neither patient required hospitalization. The man exhibited negative serology at 7- and 9-weeks post-infection. The woman exhibited negative serology at 6- and 12-weeks post-infection.
Conclusions: Large studies are essential to determine whether certain DMTs may blunt SARS-CoV-2 antibody production.
Keywords: Antibodies; COVID-19; Coronavirus; Multiple sclerosis; Ocrelizumab.